Traws Pharma, Inc. (TRAW) research

Traws Pharma, Inc.

Sector: Healthcare
Industry: Biotechnology
Last price: $0.57
As of: 2026-10-02

Traws Pharma, Inc. (TRAW): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-14.

As of 2026-08-29, the latest of: this ticker's 13F holdings load, its latest SEC filing date, and its latest signal other than 13F-derived signals. Source: SEC EDGAR filings for TRAW. Method and limitations.

COMPANY DOSSIER

See the full TRAW dossier

Price with insider and filing markers, who is positioning, fundamentals and peers for TRAW on one page. Preview it with sample data, then open it live with a free account.

Preview the TRAW dossier

Active signals for TRAW

mediumEARNINGS_BEAT2026-08-29
Q2-2026: Beat consensus by 26.9%, EPS $-0.25 vs $-0.3422 estimate
All 2026-08-29 signals →
mediumEARNINGS_BEAT2026-06-24
Q4-2024: Beat consensus by 1082.0% - EPS $95.66 vs $-9.741 estimate
All 2026-06-24 signals →
mediumEARNINGS_MISS2026-05-24
Q3-2024: Missed consensus by 41.0% - EPS $-8.81 vs $-6.2475 estimate
All 2026-05-24 signals →
mediumEARNINGS_BEAT2026-05-24
Beat consensus by 1082.0% - EPS $95.66 vs $-9.741 estimate
All 2026-05-24 signals →
mediumEARNINGS_BEAT2026-05-24
Q4-2025: Beat consensus by 150.5% - EPS $0.63 vs $-1.2485 estimate
All 2026-05-24 signals →

FREE, NO ACCOUNT

Every signal on TRAW, as it fires

You are seeing 5 of 6 signals recorded on TRAW since 2026-05-24.

The five above landed across 3 days. The other 1 were recorded on those same days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram

One tap. Live alerts, no email needed.

No non-option holdings from tracked managers in this reporting quarter. Historical quarters remain available above.

Recent SEC filings, TRAW

8-K2026-08-14
SEC EDGAR ↗
10-Q2026-08-14
SEC EDGAR ↗
8-K2026-07-31
SEC EDGAR ↗
8-K2026-07-10
SEC EDGAR ↗
8-K2026-07-09
SEC EDGAR ↗
8-K2026-06-22
SEC EDGAR ↗
8-K2026-06-12
SEC EDGAR ↗
8-K2026-05-27
SEC EDGAR ↗
8-K2026-05-26
SEC EDGAR ↗
8-K2026-05-15
SEC EDGAR ↗

TRAW against its peers

TRAW's operating margin of -640.7% ranks in the 44th percentile of 7 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-04-30.

Metric	TRAW	Peer median	Percentile	n
Revenue FY	2.8M USD	1.2M USD	75	9
Gross margin	n/a	67.0%	n/a	5
Operating margin	-640.7%	-484.3%	44	7
Net margin	328.7%	-200.8%	94	7
Return on equity	n/a	-188.9%	n/a	17
P / E	0.7x	n/a	n/a	1

Peers (19): KALA, IMRN, LGVN, APRE, ALZN, SNTI, XCUR, TOVX, CURX, ENSC, IMNN, AZTR, QNRX, CNSP, BLRX, BCLI, ZEOX, OTLC, CLGN. Left out: CUBT (no annual filing), LNAI (no annual filing), NYMXF (period gap), FBLG (no annual filing), NRSN (no annual filing), ENLV (no annual filing). Fiscal periods ending between 2025-06-30 and 2026-04-30. Every figure is one full fiscal year read from one annual filing (TRAW: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more TRAW signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to TRAWand get the insider, 13F, options, and confluence read in one view.